Secreted phospholipase B is a proven virulence factor for the pathogenic fungus Cryptococcus neoformans and exhibits three phospholipase activities in the one protein. These are phospholipase B (PLB), lysophospholipase (LPL), and lysophospholipase transacylase (LPTA). Our aim was to investigate the feasibility of using this enzyme as a target for antifungal therapy. We determined in C. neoformans var. grubii strain H99 that 82% of PLB activity was secreted but that 64% of LPL activity and 70% of LPTA activity were cell associated. Cell-associated activities (cytosolic and membrane) were further characterized, since it is likely that any fungicidal effect would depend on inhibition of these enzymes. Four commercially available compounds with structural similarities to phospholipid substrates were tested as inhibitors. These were alexidine dihydrochloride (compound A), dioctadecyldimethylammonium bromide (compound O), 1,12 bis-(tributylphosphonium)-dodecane dibromide (compound P), and decamethonium dibromide (compound D). The best phospholipase inhibitors (compounds A and P) were also the most potent antifungal agents by the standard broth microdilution test. Compound A was highly selective for secreted and cell-associated PLB activities and showed no inhibition of mammalian phospholipase A 2 at 0.25 M. Compound O, which was specific for secretory and cytosolic LPL and LPTA and membrane-associated PLB, was not antifungal. We conclude that inhibitors of cryptococcal phospholipases can be selective for fungal enzymes and intrinsically antifungal. They also provide tools for assessing the relative importance of the various enzyme activities in virulence. Our results enable further rational structure-function studies to validate the use of phospholipases as antifungal targets.Cryptococcus neoformans is the most common cause of fungal meningitis, which is fatal if it is left untreated (8, 24). Pathogenic strains of cryptococci produce a number of socalled virulence factors, one of which is a secreted phospholipase termed phospholipase B (EC 3.1.1.5) (6, 11). This phospholipase has been purified and characterized as a single protein containing three separate activities (5, 7). These include phospholipase B (PLB), which removes both acyl chains simultaneously from phospholipids; lysophospholipase (LPL), which removes the single acyl chain from lysophospholipids; and lysophospholipase transacylase (LPTA), which adds an acyl chain to lysophospholipids to form phospholipids (Fig. 1). A second secreted phospholipase containing only LPL and LPTA activities has also been identified (L. C. Wright, unpublished data). This may be the product of a newly discovered gene, CnLYSO1 (10).The structure and mechanism of action of phospholipase B are not understood, and which of the secreted phospholipase activities is important in virulence is unknown. However, secreted phospholipase B is involved in the survival of cryptococci in macrophages (11) and in the destruction of lung tissue and the production of eicosanoids, which modulate pha...